|
Is Biogen A Value Stock Yet?
Seeking Alpha Daclizumab is being developed under a collaboration agreement with Abbvie Biotherapeutics. X. X. X. GA101 (HUMANIZED ANTI-CD20 MAB) Non-Hodgkin’s Lymphoma. Humanized monoclonal antibody specific for CD20. Humanized anti-CD20 mAb is … Biogen Idec to share latest neurology data at AAN 2014Zenopa |
|
Brampton woman denied OHIP coverage for life-saving cancer drugs
Mississauga The other drug, Rituximab, is approved for second line use, but only in tandem with Fludarabine — a drug that Mitchell can’t take because she suffered an extreme, adverse reaction to it during her first bout with chemotherapy. “The drugs that my … |
Minimal residual disease associated with overall survival in leukemiaThe Oncology ReportDr. Paolo Strati and his associates studied 237 chronic lymphocytic leukemia (CLL) patients who were undergoing first-line treatment with fludarabine, cyclophospham…
New Drug Cocktail Should Boost AbbVie SharesBarron’sIn fact, AbbVie has eight other drugs in late-stage clinical trials besides its hepatitis C portfolio, including a promising leukemia drug known as ABT-199 and the multiple sclerosis treatment, dacliz…
PolyTherics, MacroGenics extend deal to develop new antibody drug conjugatesPharmaceutical Business ReviewMacroGenics has two antibody technology platforms, which includes a Dual-Affinity Re-Targeting (DART) bi-specific platform, in which a single reco…
Maintenance rituximab extended PFS, not OS in follicular lymphomaHealioPatients with follicular lymphoma who achieved stable disease with rituximab-based induction therapy demonstrated extended PFS and time to next treatment when they received maintena…
|
Company Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen Idec to Present New …
Jutia Group Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company’s Phase II clinical … |
|
Cambridge-US antibodies alliance
Business Weekly MacroGenics has two antibody technology platforms, a Dual-Affinity Re-Targeting (DART™) bi-specific platform, in which a single recombinant molecule is able to target two different antigens, and Fc-optimised antibodies with improved effector function. |
|
Biogen Idec to Present New Clinical Data from Its Robust Neurology Portfolio …
The Herald | HeraldOnline.com (press release) Daclizumab high-yield process (DAC HYP) is in late-stage clinical development for the treatment of RRMS, the most common form of MS. DAC HYP is a humanized monoclonal antibody that binds to CD25, a receptor subunit that is expressed at high levels on … Company Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen Idec to Present New …Jutia Group |
|
Biogen to Present Clinical Data from Neurology Portfolio at AAN Annual Meeting
Benzinga … beta-1a) and FAMPYRA® (prolonged-release fampridine tablets), as well as findings from the clinical programs of its MS pipeline candidates PLEGRIDY™ (peginterferon beta-1a), daclizumab high-yield process (DAC HYP) and Anti-LINGO-1 (BIIB033). |